

« Maximize cancer treatment outcomes by protecting patients from skin toxicities »

Brimonidine, a selective α -2 adrenergic receptor agonist, initially developed in ophthalmology with further potential across multiple oncology supportive care indications thanks to a novel formulation



- ✓ **Vasoconstrictor action** when applied to the skin
- ✓ Specifically targets **small capillaries** (<400 μ m) with limited systemic exposure
- ✓ Proven systemic safety and local tolerance profile



DIFFERENTIATION

- **TAR-0520** is a novel Brimonidine hydrogel **surpassing the competition** in potency and duration of effect
- Delivers a **24h of vasoconstriction** which is crucial to ensuring protective and preventive action in the targeted indications
- Formulation, regimen and use are **patent protected**
- Three target indications are eligible for **Orphan status**
- Three target indications qualify for **Expedited programs**



ONCODERMATOLOGY

- 2 out of 3 cancer patients experience cutaneous side effects
- Up to 30% of cancer patients will see their cancer treatment modified because of adverse skin reactions
- Tarian Pharma targets 4 severe skin toxicities with significant and recognized unmet needs without any approved drugs:
 - ✓ **EGFRi induced Folliculitis**
 - ✓ **Radiation induced dermatitis**
 - ✓ **Hand Foot Syndrome**
 - ✓ **Chemotherapy induced alopecia**




VALIDATION & RATIONALE

- Biological consequences of localized and superficial skin vasoconstriction:
 - ✓ **Blood flow reduction**
 - ✓ **Decrease in Oxygen in epidermis**
 - ✓ **Decreased vessel permeability**
- These properties are leveraged in the target indications to:
 - ✓ **Reduce skin bioavailability of toxic drugs administered systemically (localized pharmacokinetic exclusion)**
 - ✓ **Limit oxidative stress and ROS production**
 - ✓ **Decrease inflammation by inhibiting inflammatory cell migration and edema via serum leakage**
- Animal studies and clinical case reports support the use in the four targeted indications (data available upon request)



EPIDEMIOLOGY



- ✓ **EGFRi induced Folliculitis** : 300 K eligible patients/year
- ✓ **Radiation induced dermatitis** : 400 K
- ✓ **Hand Foot Syndrome** : 250 K
- ✓ **Chemotherapy induced alopecia** : 700 K



COMPETITIVE LANDSCAPE

- **No drug** approved in any of the targeted indications
- Off label use of marketed drugs is **unsatisfactory**
- Medical devices have **significant limitations**
- Cosmetic products are **ineffective**
- Drug candidates at early stage with **narrow applications**



LEADERSHIP TEAM & EXPERTISE

Janusz CZERNIELEWSKI
MD, PhD, MBA - CMO

- ✓ 35 years in Drug development, Medical Affairs, Marketing and Business Development
- ✓ Executive VP at Galderma for 10 years

Philippe ANDRES

- MD, Dermatologist - CEO
- ✓ 25 years in Drug development and Medical Affairs, among which 10 years spent on Brimonidine
 - ✓ Inventor of proposed uses

Gareth WINCKLE
PhD, Pharmacist

- ✓ 17 years in Formulation development
- ✓ Inventor of the new formulation TAR-0520



NEXT MILESTONE

➡ Phase 1/2a in HV & Patients: 2022